FDA Reviews Cetirizine And PPIs For Potential Serious Safety Risks
This article was originally published in The Tan Sheet
Executive Summary
Adverse event reports prompt FDA to evaluate potential links between the active ingredient in Zyrtec and oculogyric crisis, and between proton pump inhibitors and pneumonia. The agency points out the investigation does not mean a risk exists, and advises consumers to continue use of the products.
You may also be interested in...
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.